MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-18-2026
QIAGEN N.V. Accounts Receivables 2011-2026 | QGEN
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables QIAGEN N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 381 M | 385 M | 352 M | 329 M | 278 M | 274 M | 265 M | 260 M | 251 M | 231 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 385 M | 231 M | 300 M |
Quarterly Accounts Receivables QIAGEN N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 362 M | - | - | - | 381 M | - | - | - | 385 M | - | - | - | 352 M | - | - | - | 329 M | - | - | - | 278 M | - | - | - | 274 M | - | - | - | 265 M | - | - | - | 260 M | - | - | - | 251 M | - | - | - | 231 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 385 M | 231 M | 306 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B |  USA |
 |
Fulgent Genetics
FLGT
|
84.8 M | $ 17.67 | - | $ 544 M | USA |
 |
Guardant Health
GH
|
138 M | $ 119.85 | - | $ 15 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.4 B | $ 113.85 | - | $ 9.39 B |  Irlanda |
 |
Agilent Technologies
A
|
1.17 B | $ 115.08 | 0.02 % | $ 35 B | USA |
 |
Interpace Biosciences
IDXG
|
5.65 M | $ 1.8 | -1.1 % | $ 7.96 M | USA |
 |
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Illumina
ILMN
|
735 M | $ 145.23 | - | $ 23.1 B | USA |
 |
Co-Diagnostics
CODX
|
190 K | $ 9.11 | - | $ 12.1 M | USA |
 |
Castle Biosciences
CSTL
|
43.4 M | $ 19.69 | - | $ 571 M | USA |
 |
Aspira Women's Health
AWH
|
1.21 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.04 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | USA |
 |
CareDx, Inc
CDNA
|
42.6 M | $ 21.54 | - | $ 1.15 B | USA |
 |
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
359 M | $ 100.06 | - | $ 6.75 B | USA |
 |
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M |  China |
 |
Mettler-Toledo International
MTD
|
778 M | $ 1 101.33 | - | $ 22.7 B |  Schweiz |
 |
NeoGenomics
NEO
|
159 M | $ 9.27 | - | $ 1.19 B | USA |
 |
National Research Corporation
NRC
|
11.1 M | $ 19.04 | -0.21 % | $ 426 M | USA |
 |
Natera
NTRA
|
244 M | $ 200.91 | - | $ 19.8 B | USA |
 |
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | USA |
 |
Charles River Laboratories International
CRL
|
709 M | $ 156.73 | - | $ 7.77 B | USA |
 |
Personalis
PSNL
|
16.2 M | $ 8.94 | - | $ 798 M | USA |
 |
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | USA |
 |
Medpace Holdings
MEDP
|
402 M | $ 429.11 | - | $ 12.4 B | USA |
 |
Exact Sciences Corporation
EXAS
|
299 M | - | - | $ 19.8 B | USA |
 |
Myriad Genetics
MYGN
|
115 M | $ 3.85 | - | $ 357 M | USA |
 |
Twist Bioscience Corporation
TWST
|
57 M | $ 64.87 | - | $ 3.88 B | USA |
 |
Senseonics Holdings
SENS
|
127 K | $ 6.43 | - | $ 268 M | USA |
 |
Soleno Therapeutics
SLNO
|
28.2 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
731 K | $ 2.47 | - | $ 5.67 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.1 B | $ 258.45 | - | $ 21.5 B | USA |
 |
Thermo Fisher Scientific
TMO
|
8.9 B | $ 448.18 | - | $ 169 B | USA |
 |
Waters Corporation
WAT
|
829 M | $ 338.64 | - | $ 20.2 B | USA |
 |
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K |  Israel |
 |
Exagen
XGN
|
10.9 M | $ 4.62 | - | $ 99.6 M | USA |
 |
Neogen Corporation
NEOG
|
153 M | $ 9.14 | - | $ 1.98 B | USA |